Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron oral suspension in children aged 6 months to under 3 years with neurogenic detrusor overactivity
2021-005455-37Phase 3Active
- Sponsor
- Astellas Pharma
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mirabegron in detrusor hyperreflexia (DH), sponsored by Astellas Pharma. Primary endpoint: Change from baseline in maximum cystometric capacity after 24 weeks of treatment. Started Jul 2022; status: active.
02
Drugs
mirabegron
03
Conditions
detrusor hyperreflexia (DH)
Beyond the preview
Go deeper on 2021-005455-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005455-37.